Recce Pharmaceuticals (ASX:RCE) says it is nearing completion of its Phase 2 clinical trial of RECCE 327 Topical Gel (R327G) targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
The company said with 20 patients out of a total of 30 now dosed, interim data underscores R327G’s promising efficacy and safety profile.
“Data demonstrates a strong therapeutic response, with all patients completing treatment with R327G achieving positive outcomes, showing either complete cure or notable improvement. No Serious Adverse Events (SAEs) have been reported for R327G,” it said.
Recce chief medical advisor Dr Alan W Dunton said, “These interim results reflect a remarkable advancement in our journey to address critical unmet medical needs in anti-infective therapies. The robust response we are seeing with R327G is encouraging, especially as we near completion of the Phase II trial. Achieving a response of complete cure or notable improvement in all patients treated so far highlights the potential impact of R327G in treating complex bacterial infections, including diabetic foot infections.”
The company said that as the trial progresses towards completion within the current calendar, it remains focused on delivering a pioneering, synthetic anti-infective topical therapy to address ABSSSI.
